BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 24308962)

  • 1. HDAC6 mediates the acetylation of TRIM50.
    Fusco C; Micale L; Augello B; Mandriani B; Pellico MT; De Nittis P; Calcagnì A; Monti M; Cozzolino F; Pucci P; Merla G
    Cell Signal; 2014 Feb; 26(2):363-9. PubMed ID: 24308962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation.
    Matsuyama A; Shimazu T; Sumida Y; Saito A; Yoshimatsu Y; Seigneurin-Berny D; Osada H; Komatsu Y; Nishino N; Khochbin S; Horinouchi S; Yoshida M
    EMBO J; 2002 Dec; 21(24):6820-31. PubMed ID: 12486003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of GCN5 PCAF N-terminal domain reveals atypical ubiquitin ligase structure.
    Toma-Fukai S; Hibi R; Naganuma T; Sakai M; Saijo S; Shimizu N; Matsumoto M; Shimizu T
    J Biol Chem; 2020 Oct; 295(43):14630-14639. PubMed ID: 32820047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. aPKC phosphorylation of HDAC6 results in increased deacetylation activity.
    Du Y; Seibenhener ML; Yan J; Jiang J; Wooten MC
    PLoS One; 2015; 10(4):e0123191. PubMed ID: 25860570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubulin acetylation: responsible enzymes, biological functions and human diseases.
    Li L; Yang XJ
    Cell Mol Life Sci; 2015 Nov; 72(22):4237-55. PubMed ID: 26227334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo.
    Zhang Y; Li N; Caron C; Matthias G; Hess D; Khochbin S; Matthias P
    EMBO J; 2003 Mar; 22(5):1168-79. PubMed ID: 12606581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC6-p97/VCP controlled polyubiquitin chain turnover.
    Boyault C; Gilquin B; Zhang Y; Rybin V; Garman E; Meyer-Klaucke W; Matthias P; Müller CW; Khochbin S
    EMBO J; 2006 Jul; 25(14):3357-66. PubMed ID: 16810319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC6 and Ubp-M BUZ domains recognize specific C-terminal sequences of proteins.
    Hard RL; Liu J; Shen J; Zhou P; Pei D
    Biochemistry; 2010 Dec; 49(50):10737-46. PubMed ID: 21090589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
    Gold WA; Lacina TA; Cantrill LC; Christodoulou J
    J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.
    Sun F; Indran IR; Zhang ZW; Tan MH; Li Y; Lim ZL; Hua R; Yang C; Soon FF; Li J; Xu HE; Cheung E; Yong EL
    Carcinogenesis; 2015 Jul; 36(7):757-68. PubMed ID: 25908644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of cofactor-mediated stabilization and substrate recognition of the α-tubulin acetyltransferase αTAT1.
    Yuzawa S; Kamakura S; Hayase J; Sumimoto H
    Biochem J; 2015 Apr; 467(1):103-13. PubMed ID: 25602620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway.
    Dhanyamraju PK; Holz PS; Finkernagel F; Fendrich V; Lauth M
    Mol Cancer Ther; 2015 Mar; 14(3):727-39. PubMed ID: 25552369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trim58 degrades Dynein and regulates terminal erythropoiesis.
    Thom CS; Traxler EA; Khandros E; Nickas JM; Zhou OY; Lazarus JE; Silva AP; Prabhu D; Yao Y; Aribeana C; Fuchs SY; Mackay JP; Holzbaur EL; Weiss MJ
    Dev Cell; 2014 Sep; 30(6):688-700. PubMed ID: 25241935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
    Noack M; Leyk J; Richter-Landsberg C
    Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM50 regulates Beclin 1 proautophagic activity.
    Fusco C; Mandriani B; Di Rienzo M; Micale L; Malerba N; Cocciadiferro D; Sjøttem E; Augello B; Squeo GM; Pellico MT; Jain A; Johansen T; Fimia GM; Merla G
    Biochim Biophys Acta Mol Cell Res; 2018 Jun; 1865(6):908-919. PubMed ID: 29604308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIM50 promotes NLRP3 inflammasome activation by directly inducing NLRP3 oligomerization.
    Lin Y; Lv X; Sun C; Sun Y; Yang M; Ma D; Jing W; Zhao Y; Cheng Y; Xuan H; Han L
    EMBO Rep; 2022 Nov; 23(11):e54569. PubMed ID: 36178239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM50 Suppresses Pancreatic Cancer Progression and Reverses the Epithelial-Mesenchymal Transition
    Li R; Zhu L; Peng Y; Zhang X; Dai C; Liu D
    Front Oncol; 2021; 11():695740. PubMed ID: 34568024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP.
    Hu J; Huang R; Liang C; Wang Y; Wang M; Chen Y; Wu C; Zhang J; Liu Z; Zhao Q; Liu Z; Wang F; Yuan S
    Mol Cancer Res; 2023 Oct; 21(10):1107-1119. PubMed ID: 37409971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reference map of the human binary protein interactome.
    Luck K; Kim DK; Lambourne L; Spirohn K; Begg BE; Bian W; Brignall R; Cafarelli T; Campos-Laborie FJ; Charloteaux B; Choi D; Coté AG; Daley M; Deimling S; Desbuleux A; Dricot A; Gebbia M; Hardy MF; Kishore N; Knapp JJ; Kovács IA; Lemmens I; Mee MW; Mellor JC; Pollis C; Pons C; Richardson AD; Schlabach S; Teeking B; Yadav A; Babor M; Balcha D; Basha O; Bowman-Colin C; Chin SF; Choi SG; Colabella C; Coppin G; D'Amata C; De Ridder D; De Rouck S; Duran-Frigola M; Ennajdaoui H; Goebels F; Goehring L; Gopal A; Haddad G; Hatchi E; Helmy M; Jacob Y; Kassa Y; Landini S; Li R; van Lieshout N; MacWilliams A; Markey D; Paulson JN; Rangarajan S; Rasla J; Rayhan A; Rolland T; San-Miguel A; Shen Y; Sheykhkarimli D; Sheynkman GM; Simonovsky E; Taşan M; Tejeda A; Tropepe V; Twizere JC; Wang Y; Weatheritt RJ; Weile J; Xia Y; Yang X; Yeger-Lotem E; Zhong Q; Aloy P; Bader GD; De Las Rivas J; Gaudet S; Hao T; Rak J; Tavernier J; Hill DE; Vidal M; Roth FP; Calderwood MA
    Nature; 2020 Apr; 580(7803):402-408. PubMed ID: 32296183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIM50 acts as a novel Src suppressor and inhibits ovarian cancer progression.
    Qiu Y; Liu P; Ma X; Ma X; Zhu L; Lin Y; You Y; Yu W; Ma D; Sun C; Qin Z; Zhao Y; Shi J; Han L
    Biochim Biophys Acta Mol Cell Res; 2019 Sep; 1866(9):1412-1420. PubMed ID: 31176697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.